PNT
Price:
$12.5
Market Cap:
$1.33B
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast...[Read more]
Industry
Biotechnology
IPO Date
2020-07-08
Stock Exchange
NASDAQ
Ticker
PNT
According to POINT Biopharma Global Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 11.36. This represents a change of -267.81% compared to the average of -6.77 of the last 4 quarters.
The mean historical PE Ratio of POINT Biopharma Global Inc. over the last ten years is -10.59. The current 11.36 PE Ratio has changed -10832.33% with respect to the historical average. Over the past ten years (40 quarters), PNT's PE Ratio was at its highest in in the December 2022 quarter at 1.07. The PE Ratio was at its lowest in in the June 2020 quarter at -84.84.
Average
-10.59
Median
-4.50
Minimum
-40.47
Maximum
7.12
Discovering the peaks and valleys of POINT Biopharma Global Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 7.12
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -40.47
Year | PE Ratio | Change |
---|---|---|
2022 | 7.12 | -179.05% |
2021 | -9.01 | -77.74% |
2020 | -40.47 | -Infinity% |
The current PE Ratio of POINT Biopharma Global Inc. (PNT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14.12
5-year avg
-10.59
10-year avg
-10.59
POINT Biopharma Global Inc.’s PE Ratio is greater than ORIC Pharmaceuticals, Inc. (-6.10), greater than Lyra Therapeutics, Inc. (-0.15), greater than Inhibrx Biosciences, Inc. (0.13), greater than ESSA Pharma Inc. (-9.68), greater than Crinetics Pharmaceuticals, Inc. (-16.24), greater than ALX Oncology Holdings Inc. (-0.51), greater than Immatics N.V. (-13.82), greater than BioAtla, Inc. (-1.01), greater than Aerovate Therapeutics, Inc. (-0.67), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than RAPT Therapeutics, Inc. (-0.65), greater than Cyteir Therapeutics, Inc. (-3.52), greater than Pardes Biosciences, Inc. (-1.36), greater than Third Harmonic Bio, Inc. (-28.12), greater than PMV Pharmaceuticals, Inc. (-1.61), greater than Edgewise Therapeutics, Inc. (-22.92), greater than Enochian Biosciences, Inc. (-0.98), greater than Revolution Medicines, Inc. (-15.05), greater than NewAmsterdam Pharma Company N.V. (-7.42), greater than Centessa Pharmaceuticals plc (-11.07), greater than Sutro Biopharma, Inc. (-2.36), greater than Opthea Limited (-1.72), greater than HilleVax, Inc. (-0.56),
Company | PE Ratio | Market cap |
---|---|---|
-6.10 | $677.91M | |
-0.15 | $15.54M | |
0.13 | $213.66M | |
-9.68 | $267.99M | |
-16.24 | $4.25B | |
-0.51 | $88.49M | |
-13.82 | $1.12B | |
-1.01 | $106.34M | |
-0.67 | $59.18M | |
-17.73 | $8.19B | |
-0.65 | $69.81M | |
-3.52 | $108.71M | |
-1.36 | $135.19M | |
-28.12 | $514.54M | |
-1.61 | $78.83M | |
-22.92 | $2.66B | |
-0.98 | $45.38M | |
-15.05 | $7.90B | |
-7.42 | $1.63B | |
-11.07 | $1.80B | |
-2.36 | $295.89M | |
-1.72 | $689.41M | |
-0.56 | $88.12M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like POINT Biopharma Global Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like POINT Biopharma Global Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is POINT Biopharma Global Inc.'s PE Ratio?
How is the PE Ratio calculated for POINT Biopharma Global Inc. (PNT)?
What is the highest PE Ratio for POINT Biopharma Global Inc. (PNT)?
What is the 3-year average PE Ratio for POINT Biopharma Global Inc. (PNT)?
What is the 5-year average PE Ratio for POINT Biopharma Global Inc. (PNT)?
How does the current PE Ratio for POINT Biopharma Global Inc. (PNT) compare to its historical average?